Take the Right Path Upstream with MilliporeSigma

Take-the-Right-Path-Upstream-with-MilliporeSigma.png

You are developing a monoclonal antibody and a world of potential is ahead of you. However, your time to realize this potential is limited. You need to act quickly to get your biological drug to market, but have you considered the impact of your decisions as you are developing upstream? Decisions may be difficult to reverse or will require significant backtracking and resources. With our upstream ecosystem, you get your upstream development right the first time.

To successfully advance your molecule from the laboratory to the clinic quickly without sacrificing product quality, process efficiency, or patient safety, you must make the right decisions at the right time; and navigate complexities associated with business planning, cell line development, process development, technology, regulatory and risk assessment.

Our upstream ecosystem—comprised of cell line and media platforms, cell line development, cell line and product characterization services, single-use bioreactors and mixers, process development services, and next generation processing programs—gets upstream development right the first time. Our experts will save you precious time, optimize performance, improve feasibility and sustainability, while laying the groundwork for downstream success.

Related Resources

Monitoring SARS-CoV-2 interaction with ACE2

Monitoring SARS-CoV-2 interaction with ACE2

Content provided by Take the Right Path Upstream with MilliporeSigma

White Paper

In this technical note, we investigate the interactions between the following: The spike glycoprotein binding with ACE2, Spike glycoprotein and anti-spike antibodies (mAb/ pAb), The spike glycoprotein binding with mAb/pAb to inhibit the interaction with ACE2

Accelerating Cell Line and Process Development

Accelerating Cell Line and Process Development

Content provided by Take the Right Path Upstream with MilliporeSigma

White Paper

Development of a high-producing cell line supported by a robust upstream process are critical early steps in the production of monoclonal antibodies (mAbs). Optimization of this upstream workflow is essential to deliver a sufficiently high titer to...

Strategies for Upstream Intensification

Strategies for Upstream Intensification

Content provided by Take the Right Path Upstream with MilliporeSigma

White Paper

The Facility of the Future represents a transformation in how biologics are developed and manufactured.